Knowthestock.com
ROIV - Roivant Sciences Ltd

Sell

Moderate Growth and ImprovingEarnings/Profit is Negative
WeakStrong
WeakStrong

40%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 148.83%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -68.71%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 37.91
Debt Ratio is 0.04
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative but improving
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Roivant Sciences Ltd (ROIV) - http://roivant.com/
roivant is a global healthcare company focused on rapidly developing innovative medicines. we believe that the key to unlocking innovation in drug discovery and drug commercialization is to reduce the time and cost of the drug development process. we solve this problem by building vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in pharma r&d; and commercialization. the goal of our model is to ensure that important medicines rapidly reach patients who suffer from serious diseases. we focus on disease areas where the magnitude of r&d; investment from industry is disproportionately low relative to societal medical needs. we also launch new vants to directly improve the process of developing and commercializing new medicines. our pipeline spans multiple therapeutic areas through partnerships with academic institutions and biopharmaceutical companies, including tak
Exchange - NASDAQ
Industry - Research and Development in Biotechnology (except Nanobiotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Matthew Gline
Employees - 309
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.